Russian Direct Investment Fund and Cadila Pharmaceuticals to invest in project for injectable drug production in Russia. Investment estimated at 10 billion rubles, with RDIF contributing up to 1.5 billion rubles. Enterprise launch planned for 2027.
Pharma complex to produce over 1 billion drug units yearly, including for cardiovascular diseases and diabetes. Plans to produce 1,500 tons of active ingredients annually, with potential for expansion. A new enterprise is set to introduce drugs that have not been previously manufactured in Russia.